SEC Info - Opko Health, Inc. - ‘8-K/A’ for 3/28/24

SEC Info℠

Home

Help

Please Sign In

Opko Health, Inc. – ‘8-K/A’ for 3/28/24

On: Thursday, 3/28/24, at 11:06am ET · For: 3/28/24 · Accession #: 1437749-24-9735 · File #: 1-33528

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Opko Health, Inc.                 8-K/A:7,9   3/28/24   13:5.4M                                   RDG Filings/FA

Amendment to Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K/A       Amendment to Current Report                         HTML     27K 
 2: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML    549K 
                Liquidation or Succession                                        
 3: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
 8: R1          Document And Entity Information                     HTML     48K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
13: XML         XBRL Instance -- opk20240328_8ka_htm                 XML     15K 
 9: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 5: EX-101.DEF  XBRL Definitions -- opk-20240328_def                 XML     38K 
 6: EX-101.LAB  XBRL Labels -- opk-20240328_lab                      XML     49K 
 7: EX-101.PRE  XBRL Presentations -- opk-20240328_pre               XML     38K 
 4: EX-101.SCH  XBRL Schema -- opk-20240328                          XSD     14K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    20K 
12: ZIP         XBRL Zipped Folder -- 0001437749-24-009735-xbrl      Zip    130K

‘8-K/A’ — Amendment to Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C:

i 8KA Project Sunset 3-28-24 i true i 0000944809 0000944809 2024-03-28 2024-03-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM i 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 28, 2024

i OPKO Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

i Delaware		i 001-33528		i 75-2402409
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i 4400 Biscayne Blvd.	i Miami,	i Florida		i 33137
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: ( i 305) i 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $0.01 per share	i OPK	i NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

This filing amends Item 9.01 of the Current Report on Form 8-K filed March 28, 2024 by OPKO Health, Inc. (the “OPKO”), and specifically Exhibit 99.1, Investor Presentation, to replace the previously used January presentation with OPKO’s updated presentation.

ITEM 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description

2.1*		Asset Purchase Agreement, dated as of March 27, 2024 by and among BioReference Health, LLC, OPKO Health, Inc. and Laboratory Corporation of America Holdings
99.1		Investor Presentation, dated March 27, 2024
104		Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document

* Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OPKO Health, Inc.

	By:	/s/ *Steven D. Rubin*
Date: March 28, 2024	Name:	Steven D. Rubin
	Title:	Executive Vice President-Administration

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K/A’ Filing	Date	Other Filings

Filed on / For Period end:	3/28/24	8-K, DEF 14A, PRE 14A
		List all Filings

↑Top

Filing Submission 0001437749-24-009735 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)